Out of 6 analysts covering Cerulean Pharmaceuticals (NASDAQ:CERU), 0 rate it “Buy”, 0 “Sell”, while 0 “Hold”. This means NaN are positive. Cerulean Pharmaceuticals was the topic in 7 analyst reports since August 7, 2015 according to StockzIntelligence Inc. Below is a list of Cerulean Pharma Inc (NASDAQ:CERU) latest ratings and price target changes.
09/03/2016 Broker: JMP Securities Rating: Market Outperform Old Target: $16.00 New Target: $9.00 Maintain
24/02/2016 Broker: Barclays Capital Rating: Overweight Old Target: $8.00 New Target: $5.00 Maintain
06/01/2016 Broker: Janney Capital Rating: Buy Initiate
About 27,868 shares traded hands. Cerulean Pharma Inc (NASDAQ:CERU) has declined 29.25% since September 9, 2015 and is downtrending. It has underperformed by 36.49% the S&P500.
Cerulean Pharma Inc. is a clinical-stage, oncology-focused company. The company has a market cap of $93.10 million. The Firm applies its Dynamic Tumor Targeting platform to develop differentiated therapies. It currently has negative earnings. The Company’s platform utilizes nanoparticle-drug conjugates , which consist of polymers that are covalently linked to anti-cancer therapeutics or payloads.
The institutional sentiment decreased to 1.45 in 2015 Q3. Its down 5.55, from 7 in 2015Q2. The ratio turned negative, as 5 funds sold all Cerulean Pharma Inc shares owned while 6 reduced positions. 7 funds bought stakes while 9 increased positions. They now own 16.89 million shares or 33.66% less from 25.46 million shares in 2015Q2.
Polaris Venture Management Co Iv Llc holds 9.25% of its portfolio in Cerulean Pharma Inc for 1.44 million shares. Polaris Venture Management Co. V L.L.C. owns 3.29 million shares or 8.2% of their US portfolio. Moreover, Deer Vii & Co. Ltd. has 0.58% invested in the company for 166,675 shares. The California-based Wall Street Associates has invested 0.33% in the stock. Cormorant Asset Management Llc, a Massachusetts-based fund reported 551,354 shares.
Cerulean Pharma Inc - Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with MarketBeat.com’s FREE daily email newsletter.